JPWO2020115183A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020115183A5 JPWO2020115183A5 JP2021531796A JP2021531796A JPWO2020115183A5 JP WO2020115183 A5 JPWO2020115183 A5 JP WO2020115183A5 JP 2021531796 A JP2021531796 A JP 2021531796A JP 2021531796 A JP2021531796 A JP 2021531796A JP WO2020115183 A5 JPWO2020115183 A5 JP WO2020115183A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- crystalline form
- expressed
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 201000011510 cancer Diseases 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000005209 Hematologic Disease Diseases 0.000 claims 3
- 210000000987 Immune System Anatomy 0.000 claims 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 3
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 210000001672 Ovary Anatomy 0.000 claims 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 206010046766 Uterine cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 3
- 230000003211 malignant Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- PKYIMGFMRFVOMB-UHFFFAOYSA-N ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C Chemical compound ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C PKYIMGFMRFVOMB-UHFFFAOYSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000005712 crystallization Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- -1 glidants Substances 0.000 claims 2
- 238000010899 nucleation Methods 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 1
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- LJWKFGGDMBPPAZ-UHFFFAOYSA-N ethoxyethane;toluene Chemical compound CCOCC.CC1=CC=CC=C1 LJWKFGGDMBPPAZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634.9 | 2018-12-06 | ||
| EP18306634 | 2018-12-06 | ||
| PCT/EP2019/083773 WO2020115183A1 (en) | 2018-12-06 | 2019-12-05 | New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511495A JP2022511495A (ja) | 2022-01-31 |
| JPWO2020115183A5 true JPWO2020115183A5 (fi) | 2022-11-22 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531796A Pending JP2022511495A (ja) | 2018-12-06 | 2019-12-05 | Ｍｃｌ－１阻害剤の新しい結晶形、その調製プロセス及びそれらを含有する医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220017533A1 (fi) |
| EP (1) | EP3891156B1 (fi) |
| JP (1) | JP2022511495A (fi) |
| KR (1) | KR20210100148A (fi) |
| CN (1) | CN113166169A (fi) |
| AR (1) | AR117255A1 (fi) |
| AU (1) | AU2019391329A1 (fi) |
| BR (1) | BR112021010072A2 (fi) |
| CA (1) | CA3121363A1 (fi) |
| DK (1) | DK3891156T3 (fi) |
| EA (1) | EA202191534A1 (fi) |
| ES (1) | ES2971258T3 (fi) |
| FI (1) | FI3891156T3 (fi) |
| HR (1) | HRP20240211T1 (fi) |
| HU (1) | HUE065266T2 (fi) |
| IL (1) | IL283656A (fi) |
| LT (1) | LT3891156T (fi) |
| MA (1) | MA54379B1 (fi) |
| MX (1) | MX2021006702A (fi) |
| PL (1) | PL3891156T3 (fi) |
| PT (1) | PT3891156T (fi) |
| RS (1) | RS65047B1 (fi) |
| SI (1) | SI3891156T1 (fi) |
| TW (1) | TW202039511A (fi) |
| WO (1) | WO2020115183A1 (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Ｍｃｌ－１抑制劑與抗體藥物接合物之組合 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 KR KR1020217020808A patent/KR20210100148A/ko unknown
- 2019-12-05 TW TW108144437A patent/TW202039511A/zh unknown
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 AU AU2019391329A patent/AU2019391329A1/en active Pending
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 JP JP2021531796A patent/JP2022511495A/ja active Pending
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/en active Application Filing
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 US US17/295,521 patent/US20220017533A1/en active Pending
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 CA CA3121363A patent/CA3121363A1/en active Pending
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/en active Active
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
-
2021
- 2021-06-02 IL IL283656A patent/IL283656A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4836404B2 (ja) | 抗癌化合物ｚｄ１８３９の新規結晶形 | |
| JP2016528179A (ja) | 製造方法及びｍｄｍ２阻害剤の結晶形 | |
| JP2013512956A5 (fi) | ||
| JP2013545812A (ja) | ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形 | |
| CN110590749B (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| AU2016265922B2 (en) | A pharmaceutical co-crystal and use thereof | |
| JP2021152051A (ja) | ロルラチニブマレイン酸塩の結晶質形態 | |
| JP2019516749A5 (fi) | ||
| JP2024056684A (ja) | 置換フェニル又はピリジニル部分を有するｓｅｒｄ三環化合物の製造方法 | |
| WO2020224626A9 (zh) | 用作激酶抑制剂的化合物及其应用 | |
| WO2005080381A1 (en) | New polymorphic forms of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics | |
| JP7314319B2 (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| JPWO2020115183A5 (fi) | ||
| HRP20240211T1 (hr) | Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora | |
| CN116478175A (zh) | 喜树碱-7-乙基胺衍生物及其制备方法和应用 | |
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| KR102458566B1 (ko) | 메푸파리브 히드로클로라이드 다결정형 물질 및 이의 제조방법과 응용 | |
| CN115521312A (zh) | Adagrasib的固体形式及其制备方法 | |
| TWI535724B (zh) | 埃克替尼磷酸鹽的新晶型及其用途 | |
| US20100311784A1 (en) | Stereoselective process and crystalline forms of a camptothecin | |
| JP2020172512A (ja) | Ｍｇｌｕ５受容体のネガティブアロステリック調節因子の多型 | |
| JP2012524769A (ja) | ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンの製造方法 | |
| RU2021119029A (ru) | Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции | |
| EP2027126A2 (en) | Crystalline forms of 5-chloro-6- (2, 6-difluoro-4-[3- (methylamino) propoxy] phenyl)-n-((1s)-2, 2, 2,-trifluoro-1-methylethyl][1,2,4]triazolo [1,5-a]pyrimidin-7-amine salts | |
| JP2022508864A (ja) | チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法 |